Market News

Stay updated with the latest market trends, earnings, and economic indicators.

Showing news for:VENUSREM
Clear all filters
NEWS
positive
Business Standard - Markets 45d ago

Venus Remedies consolidated net profit rises 126.19% in the March 2026 quarter

Sales rise 33.05% to Rs 259.40 crore

VENUSREMHealthcare
NEWS
positive
Business Standard - Markets 45d ago

Venus Remedies standalone net profit rises 193.78% in the March 2026 quarter

Sales rise 31.65% to Rs 259.01 crore

VENUSREMHealthcare
Venus Remedies gets Saudi FDA approval for speciality oncology therapy
positive
ET Markets - Industry 49d ago

Venus Remedies gets Saudi FDA approval for speciality oncology therapy

Venus Remedies Limited has secured its first global marketing authorization for its specialty oncology therapy, Plerixafor, from the Saudi Food and Drug Authority (SFDA). This hematopoietic stem cell mobilizer is crucial for patients undergoing stem cell transplantation for multiple myeloma and non-Hodgkin lymphoma.

GLOBALSPECIALITYVENUSREMVIDHIINGChemicalsConsumer Services
NEWS
positive
Business Standard - Markets 50d ago

Venus Remedies receives Saudi FDA approval for Plerixafor

Venus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets.

RELIANCERELINFRAVALUEVENUSREMVIDHIINGChemicalsFinancial Services
Venus Remedies expands Latin America presence with Argentina nod for antibiotic
positive
ET Markets - Industry 65d ago

Venus Remedies expands Latin America presence with Argentina nod for antibiotic

Venus Remedies has received approval in Argentina for its antibiotic Ceftriaxone. This marks a significant step in the company's Latin America expansion. Argentina is a key market for critical care therapies. Ceftriaxone is vital for treating serious bacterial infections. This authorization strengthens Venus Remedies' global presence and commitment to accessible anti-infective treatments.

GLOBALVENUSREMVITALChemicalsConsumer Services
Momentum Stocks: Solex Energy, Sagardeep Alloy, Grand Continent rally sheer momentum
positive
Moneycontrol NaNd ago

Momentum Stocks: Solex Energy, Sagardeep Alloy, Grand Continent rally sheer momentum

A few stocks saw sharp intraday moves and hit upper circuits. Venus Remedies, Modison, Gujarat Raffia Industries, GE Power India were locked in the upper band, reflecting strong demand and limited supply—often a sign of bullish near-term sentiment.

DPELENERGYGCHOTELSGIPCLGKENERGYGUJRAFFIAGVPILKPELMODISONLTDMOMENTUMPIGLSAGARDEEPSOLEXVENUSREMCapital GoodsConstruction
Momentum Stocks: Elgi Equipments, Wockhardt, Triveni Turbine, Adani Total Gas hit 52-week high
positive
Moneycontrol NaNd ago

Momentum Stocks: Elgi Equipments, Wockhardt, Triveni Turbine, Adani Total Gas hit 52-week high

Hitech Corporation, Venus Remedies, Aditya Infotech were locked in the upper band, reflecting strong demand and limited supply—often a sign of bullish near-term sentiment.

3IINFOLTDADANIENTAONETMMQ50ATGLCPPLUSELGIEQUIPHITECHHITECHCORPMOMENTUMTOTALTRITURBINETRIVENIVENUSREMWOCKPHARMACapital GoodsFast Moving Consumer Goods
Momentum Stocks: Coffee Day Enterprises, E2E Networks, Hitech Corporation hit upper circuit
positive
Moneycontrol NaNd ago

Momentum Stocks: Coffee Day Enterprises, E2E Networks, Hitech Corporation hit upper circuit

Coffee Day Enterprises, E2E Networks, Hitech Corporation, Venus Remedies were locked in the upper band, reflecting strong demand and limited supply—often a sign of bullish near-term sentiment.

COFFEEDAYE2EHITECHHITECHCORPMOMENTUMVENUSREMCapital GoodsConsumer Services